SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Genmab Reports 28.2-Month Median Survival in Combination Trial

Genmab reported 28.2-month median survival in a trial combining petosemtamab with pembrolizumab.

GMAB

Related stories